Peptron Gets IND Approval for Phase 1 Trial of "Once-Monthly" Obesity Treatment
Peptide-based innovative drug developer Peptron is launching a clinical trial of an obesity treatment designed to reduce dosing frequency from once a week to once a month.
On November 19, Peptron announced that it had received approval from the Ministry of Food and Drug Safety for the Investigational New Drug (IND) application for PT403, a once-monthly, long-acting semaglutide obesity treatment that uses the company's SmartDepot drug-delivery platform technology, which extends the duration of a drug's effects.
Following the approval, Peptron plans to conduct a Phase 1 clinical trial of PT403 in a total of 22 healthy adults at Chungnam National University Hospital. The trial will assess the safety, tolerability, and pharmacokinetic (PK) properties of PT403 after a single subcutaneous dose.
The trial is designed as a randomized, placebo-controlled, double-blind study with an active reference group. Doses will be escalated sequentially across three cohorts. Dosing in each subsequent cohort is planned to begin after the Safety Review Committee (SRC) reviews safety and tolerability data from the previous cohort.
PT403 is a long-acting injectable being developed to extend the dosing interval for semaglutide, which is widely used globally to treat obesity and diabetes, from once a week to once a month by applying Peptron's SmartDepot technology.
Following the IND approval, the company is proceeding with the steps required to initiate the clinical trial and aims to administer the first dose to a participant in December 2026. Based on the results obtained from the trial, it plans to refine its strategy for subsequent clinical development and build clinical evidence to support global development.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Peptron representative said, "This IND approval is significant because the once-monthly semaglutide formulation, produced at our own GMP facility using our SmartDepot technology, has entered the full-fledged clinical development stage. We will advance the PT403 clinical trial without disruption, systematically assess its safety, tolerability, and pharmacokinetic properties, and build clinical evidence to support global development."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.